Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of XNW5004 versus chidamide in relapsed or refractory peripheral T-cell lymphoma
CTR20244727Phase 3Active
- Sponsor
- Sinovent
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of igermetostat in peripheral T-cell lymphoma (PTCL), sponsored by Sinovent. Started Apr 2025; status: active.
02
Drugs
igermetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20244727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244727.